Evidence map›Paper›PMID 25793762›Full record

Observational studyPloS one2015

Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

Anouk N A van der Horst-Schrivers, Wim J Sluiter, Anneke C Muller Kobold, Bruce H R Wolffenbuttel, John T M Plukker, Peter H Bisschop, John M de Klerk, Imad Al Younis, Paul Lips, Jan W Smit and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Anouk N A van der Horst-SchriversDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Wim J SluiterDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Anneke C Muller KoboldDepartment of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Bruce H R WolffenbuttelDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
John T M PlukkerDepartment of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Peter H BisschopAcademic Medical Center, University of Amsterdam, Department of Endocrinology, Amsterdam, the Netherlands.
John M de KlerkMeander Medical Center Amersfoort, Department of Nuclear Medicine, Amersfoort, the Netherlands.
Imad Al YounisLeiden University Medical Center, Department of Nuclear Medicine and Molecular Imaging, Leiden, the Netherlands.
Paul LipsVU University Medical Center, Department of Internal Medicine/Endocrinology, Amsterdam, the Netherlands.
Jan W SmitRadboud University Nijmegen Medical Center, Department of Internal Medicine, Nijmegen, the Netherlands.
Adrienne H BrouwersDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Thera P LinksDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
University Medical Center Groningen · NLAcademic Medical Center · NLAmsterdam UMC Location VUmc · NLLeiden University Medical Center · NLMeander Medisch Centrum · NLRadboud University Nijmegen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with differentiated thyroid cancer (DTC) are treated with (near)-total thyroidectomy followed by remnant ablation. Optimal radioiodine-131 (131I) uptake is achieved by withholding thyroid hormone (THW), pretreatment with recombinant human Thyrotropin Stimulating Hormone (rhTSH) is an alternative. Six randomized trials have been published comparing THW and rhTSH, however comparison is difficult because an uniform definition of ablation success is lacking. Using a strict definition, we performed an observational study aiming to determine the efficacy of rhTSH as preparation for remnant ablation. PATIENTS AND

methodsAdult DTC patients with, tumor stage T1b to T3, Nx, N0 and N1, M0 were included in a prospective multicenter observational study with a fully sequential design, using a stopping rule. All patients received remnant ablation with 131I using rhTSH. Ablation success was defined as no visible uptake in the original thyroid bed on a rhTSH stimulated 150 MBq 131I whole body scan (WBS) 9 months after remnant ablation, or no visible uptake in the original thyroid bed on a post therapeutic WBS when a second high dose was necessary.

resultsAfter interim analysis of the first 8 patients, the failure rate was estimated to be 69% (90% confidence interval (CI) 20-86%) and the inclusion of new patients had to be stopped. Final analysis resulted in an ablation success in 11 out of 17 patients (65%, 95% CI 38-86%).

conclusionAccording to this study, the efficacy of rhTSH in the preparation of 131I ablation therapy is inferior, when using a strict definition of ablation success. The current lack of agreement as to the definition of successful remnant ablation, makes comparison between different ablation strategies difficult. Our results point to the need for an international consensus on the definition of ablation success, not only in routine patient's care but also for scientific reasons.

trial registrationDutch Trial Registration NTR2395.

Indexed as

AdultAgedFemaleHumansMaleMiddle AgedProspective StudiesRandomized Controlled Trials as TopicThyroglobulinThyroidectomyThyroid GlandThyroid NeoplasmsThyrotropinTreatment OutcomeThyroglobulinThyrotropin

Identifiers

PMID25793762
PMCPMC4367989
OpenAlexW2157999775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.